Herantis Pharma Secures €12.2M in Funding, Advances Parkinson’s Therapy Toward Phase 2
Event summary
- Herantis Pharma raised €4.2M in a directed share issue and secured an €8.0M Horizon Europe 2025 grant, totaling €12.2M in new funding for Phase 2 preparations.
- Phase 1b biomarker data confirmed biological activity of HER-096, supporting its mechanism in Parkinson’s disease.
- FDA provided positive feedback on HER-096’s Investigational New Drug (IND) application path, enhancing U.S. market attractiveness.
- Dr. Juha Savola appointed as Chief Medical Officer, bringing 25+ years of global drug development experience.
- Phase 2 study preparations ongoing, with target initiation in H1 2027 pending regulatory approvals.
The big picture
Herantis Pharma’s strategic advancements in 2026—including €12.2M in funding, positive FDA feedback, and Phase 1b data validation—position HER-096 as a promising candidate in the competitive Parkinson’s disease therapy landscape. The company’s ability to translate these milestones into a successful Phase 2 trial will be critical in attracting larger partners and securing long-term viability in a market dominated by established players and emerging biotechs.
What we're watching
- Clinical Trial Timing
- Whether Herantis can maintain its H1 2027 target for Phase 2 initiation amid regulatory and operational hurdles.
- Partnering Strategy
- How ongoing discussions with global and U.S. partners may accelerate HER-096’s commercialization path.
- Financial Sustainability
- The pace at which Herantis can secure additional financing to support Phase 2 execution and beyond.
Related topics